Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.
Clinical trial NCT05253911 · COMPLETED
Trial details
- NCT number
- NCT05253911
- Sponsor
- iOMEDICO AG
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2022-05-21
- Primary completion
- 2025-06-30
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.